Utebzi (tebipenem) Medical Education
US Medical Affairs provides evidence-based scientific information and educational materials for US healthcare professionals.
References
1. Prescribing Information for UTEBZI.
2. Hong DK, et al. Oral tebipenem pivoxil hydrobromide vs intravenous imipenem-cilastatin in patients with complicated urinary tract infections or acute pyelonephritis: efficacy and safety results from the phase 3 PIVOT-PO study. Presented at IDWeek, 19–22 October 2025, Atlanta, GA. Presentation 173.
3. Access to Medicine Foundation. Lack of access to medicine is a major driver of drug resistance. How can pharma take action? 2022. Accessed July 1, 2026.
4. World Health Organization. Antimicrobial resistance. 2023. Accessed July 1, 2026.
You are now leaving GSK’s website
This webinar was developed by the Coalition for Global Hepatitis Elimination and is supported by GSK. GSK had no input on webinar content or speakers.
This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.